These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11591605)

  • 21. [Bosentan: a new pillar in the treatment of pulmonary hypertension?].
    Matthes J; Groner F
    Dtsch Med Wochenschr; 2006 May; 131(18):1031-4. PubMed ID: 16673229
    [No Abstract]   [Full Text] [Related]  

  • 22. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blockade of endothelin receptor with bosentan--a new principle of treatment in pulmonary arterial hypertension].
    Nielsen-Kudsk JE
    Ugeskr Laeger; 2003 Jul; 165(29):2891-4. PubMed ID: 12908360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical management of primary pulmonary hypertension.
    McLaughlin VV
    Expert Opin Pharmacother; 2002 Feb; 3(2):159-65. PubMed ID: 11829729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From the Food and Drug Administration.
    Crawford LM
    JAMA; 2002 Jul; 288(1):36. PubMed ID: 12090852
    [No Abstract]   [Full Text] [Related]  

  • 29. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
    Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to bosentan in children with pulmonary hypertension.
    Maiya S; Hislop AA; Flynn Y; Haworth SG
    Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy of mild, but symptomatic pulmonary hypertension].
    Reichenberger F; Seeger W; Nitschmann S
    Internist (Berl); 2009 Mar; 50(3):374-6. PubMed ID: 19225745
    [No Abstract]   [Full Text] [Related]  

  • 33. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological characteristics and clinical efficacy of bosentan].
    Fujimoto K; Ikenoya S
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):407-18. PubMed ID: 16462092
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pulmonary hypertension].
    Olschewski H; Ghofrani A; Wiedemann R; Rose F; Enke B; Gessler T; Voswinckel R; Kohstall M; Grimminger F; Seeger W
    Internist (Berl); 2002 Dec; 43(12):1498, 1501-9. PubMed ID: 12607389
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of pulmonary arterial hypertension.
    Humbert M; Sitbon O; Simonneau G
    N Engl J Med; 2004 Sep; 351(14):1425-36. PubMed ID: 15459304
    [No Abstract]   [Full Text] [Related]  

  • 37. Has the 6-min walk distance run its course?
    McLaughlin VV
    Chest; 2012 Dec; 142(6):1363-1365. PubMed ID: 23208324
    [No Abstract]   [Full Text] [Related]  

  • 38. A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.
    Wang S; Yu M; Zheng X; Dong S
    Drug Deliv; 2018 Nov; 25(1):1898-1909. PubMed ID: 30442035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treprostinil (Remodulin) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2002 Sep; 44(1139):80-2. PubMed ID: 12237619
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of primary pulmonary hypertension.
    Handa S
    Intern Med; 2002 Oct; 41(10):757-8. PubMed ID: 12412989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.